ACOG

On August 21, the FDA approved the first RSV vaccine for use in pregnant individuals between 32 and 36 weeks to protect newborns and infants against severe RSV disease in the first six months after birth. ACOG is supportive of this RSV vaccine being approved and available to pregnant individuals and looks forward to CDC’s Advisory Committee on Immunization Practice’s recommendations related to the implementation of this vaccine. Implementation considerations to be addressed  include  co-administration with other maternal immunizations, the relationship between the maternal RSV vaccine and the recently recommended monoclonal antibody for infants, and whether all patients will have access to the vaccine. ACOG guidance related to maternal RSV vaccination will be forthcoming following careful review of FDA indications and CDC recommendations.